- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00843050
A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma
Single-Arm, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of P276-00 in Patients With Relapsed and/or Refractory Mantle Cell Lymphoma
Studienübersicht
Detaillierte Beschreibung
Despite response rates of up to 97% with first-line standard or high-intensity chemotherapy, with or without stem-cell transplantation, most patients of mantle cell lymphoma (MCL)relapse.Prognosis of MCL after first relapse is very poor with median survival of around 1 to 2 years. Therefore, novel therapies are required for relapsed and/or refractory MCL.Overexpression of Cyclin D1 as a result of t(11;14)(q13;q32) translocation is the hallmark of MCL.It is postulated that Cyclin D1 may also have an oncogenic role independent of pRb in MCL.Therefore, inhibition of Cdk4-Cyclin D1 is a potentially promising target in MCL. P276-00 is a potent Cdk4-Cyclin D1 inhibitor worth exploring for its efficacy in MCL. Hence, this Phase II study is planned to examine the efficacy and safety of P276-00 in the treatment of patients with relapsed and/or refractory MCL.
This is an open-label, single-arm, 2-stage trial. Approximately 35 patients are planned to be enrolled into the study to obtain a total of 25 efficacy evaluable patients (patients who complete at least 2 cycles of study treatment and have tumor measurements at the end of 2 cycles). A total of 15 efficacy evaluable patients are planned to be treated in Stage I of the study. If ≥1 response (CR or PR) of any duration or ≥2 stable disease (SD) for ≥4 cycles are seen in the Stage I, then the study will continue into Stage II, in which additional patients will be treated until there are 10 additional efficacy evaluable patients.The study is divided into 3 periods: Screening, Treatment, and Follow-up. During the Screening Period, patients will provide written informed consent and be evaluated for inclusion and exclusion criteria. During the Treatment Period, patients will be administered P276-00 as intravenous (iv) infusion on Days 1 to 5 of each 21-day cycle for a minimum of 6 cycles and a maximum of 12 cycles, or until progressive disease (PD) or unacceptable toxicity occurs. Safety and efficacy evaluations will be done on Days 1 to 5 and 11 of each cycle, and on Day 21 of every 2 cycles. Pharmacokinetic (PK) assessments will be done on Cycle 1, Day 1 (pre-dose and post-dose time points), and optional biomarker assessments will be done pre-dose within 4 weeks of Day 1 and post-dose on Day 4 or 5. The End-of-Last-Cycle Visit will occur at the end of Cycle 6, or if the patient continues study treatment beyond Cycle 6, it will occur at the end of the patient's last cycle; if the patient discontinues early, these assessments will be done as an Early Exit Visit. The Follow-up Visit will occur 4 weeks (±1 week) after the End-of-Last-Cycle Visit (or Early Exit Visit) for final safety assessments.Objective response rate is the primary end point for this study. Response evaluation will be performed using the International Working Group (IWG) revised response criteria for malignant lymphoma.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
Delhi
-
New Delhi, Delhi, Indien, 10029
- Institute Rotary Cancer Hospital, All India Institute of Medical Sciences
-
-
Karnataka
-
Bangalore, Karnataka, Indien, 34
- St. Johns Medical College & Hospital
-
-
Kerala
-
Calicut, Kerala, Indien, 16
- Malabar Institute of Medical Sciences
-
-
Maharashtra
-
Mumbai, Maharashtra, Indien, 400 026
- Jaslok Hospital and Research Centre
-
Mumbai, Maharashtra, Indien, 400012
- Tata Memorial Hospital
-
Nagpur, Maharashtra, Indien, 440012
- Cancer Care Clinic and Hospital
-
-
Tamil nadu
-
Madurai, Tamil nadu, Indien, 625107
- Meenakshi mission hospital and research centre
-
-
-
-
Arizona
-
Phoenix, Arizona, Vereinigte Staaten, 85054
- Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Phoenix, Arizona
-
Scottsdale, Arizona, Vereinigte Staaten, 85259
- Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Arizona
-
-
Minnesota
-
Rochester, Minnesota, Vereinigte Staaten, 55905
- College of Medicine, Mayo Clinic
-
-
New Jersey
-
Hackensack, New Jersey, Vereinigte Staaten, 07601
- Hackensack University Medical Center
-
-
Ohio
-
Canton, Ohio, Vereinigte Staaten, 44718
- Gabrail Cancer Center Research
-
Dover, Ohio, Vereinigte Staaten, 44622
- Gabrail Cancer Center Research
-
-
Tennessee
-
Nashville, Tennessee, Vereinigte Staaten, 37232-5505
- Vanderbilt University Medical Center
-
-
Texas
-
New Braunfels, Texas, Vereinigte Staaten, 78130
- Cancer Care Centers of South Texas
-
San Antonio, Texas, Vereinigte Staaten, 78229
- Cancer Care Centers of South Texas
-
-
Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84112
- Huntsman Cancer Institute, 2000 Circle of Hope, Room 2145
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98109
- Seattle Cancer Care Alliance
-
Seattle, Washington, Vereinigte Staaten, 98195
- Department of Medicine, University of Washington
-
-
Wisconsin
-
Madison, Wisconsin, Vereinigte Staaten, 53792-5156
- Dept of Hematology/Oncology, University of Wisconsin- Madison
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Age ≥18 years
- Histological diagnosis of MCL and presence of either nuclear Cyclin D1 positivity by immunohistochemistry or t(11;14) by fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), or conventional karyotyping
- Documented progression or relapse after at least 1 line of prior chemotherapy
- Presence of measurable disease
- ECOG performance status 0, 1, or 2
- Life expectancy of at least 3 months
- Ability to understand and the willingness to sign a written informed consent document (ICD)
- Full recovery from all prior treatment toxicities of Common Terminology Criteria for Adverse Events (CTCAE) Grade ≤ 1
Exclusion Criteria:
- Prior radiation therapy, chemotherapy or biologic/targeted anticancer agents within 4 weeks of study drug administration
- Prior treatment with monoclonal antibodies or any radio- or toxin- immunoconjugates within 3 months of study drug administration; however, a patient who has had rituximab treatment within 3 months and has had PD after such treatment is allowed in the study.
- Prior allogeneic stem cell transplantation within 1 year of study drug administration
- Current or prior CNS lymphoma
- QTc > 450 msec
- Unstable angina, myocardial infarction, CHF or stroke within previous 6 months of study drug administration
- Presence of active and serious comorbidity and uncontrolled illness other than MCL
- History of other prior malignancies except for properly treated basal cell or squamous cell carcinoma of skin, in situ cervical cancer, in situ breast cancer or early stage prostate cancer
- Hemoglobin <8.0 gm/dL
- Absolute neutrophil count <1000/mm3
- Platelet count <50,000/mm3
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) >3 × institutional upper limit of normal (ULN) (> 5 × institutional ULN if liver is involved with lymphoma or if patient has Gilbert's Disease)
- Total bilirubin, >1.5 × institutional ULN (> 3 × institutional ULN if liver is involved with lymphoma or if patient has Gilbert's Disease)
- Serum creatinine >1.5 × institutional ULN
- Patients known to be suffering from infection with human immunodeficiency virus (HIV), tuberculosis, Hepatitis C or Hepatitis B
- Pregnant or lactating women
- Women of childbearing potential or men not willing to use at least 2 approved methods of contraception (one of which being a barrier method) after signing the ICD, during the entire study and for at least 4 weeks following withdrawal from the study
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: P276-00
P276-00: All patients will receive P276-00 185 mg/m2/day as intravenous infusion over 30 minutes in 200 ml of 5% dextrose from day 1 to day 5 in each 21 days cycle for minimum 6 and maximum 12 cycles or until there is progression of disease or unacceptable toxicity
|
P276-00: All patients will receive P276-00 185 mg/m2/day as intravenous infusion over 30 minutes in 200 ml of 5% dextrose from day 1 to day 5 in each 21 days cycle for minimum 6 and maximum 12 cycles or until there is progression of disease or unacceptable toxicity
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Best Overall Objective Response Rate
Zeitfenster: End of every 2 cycles and end of the study treatment
|
The primary efficacy endpoint is the proportion of subjects achieving an objective response.
The proportion of patients achieving an objective response is the best overall objective response rate.
|
End of every 2 cycles and end of the study treatment
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Duration of Response
Zeitfenster: End of the study treatment
|
It is defined as the time from when the measurement criteria are met for complete or partial response until the first date that recurrent or progressive disease is objectively or clinically documented.
|
End of the study treatment
|
Time to Progression
Zeitfenster: End of study treatment
|
It is defined as the time from day 1 of the study drug administration until the first date of progressive disease.
|
End of study treatment
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Brad Kahl, MD, Director of the Lymphoma Service and Associate Professor of Medicine, University of Wisconsin- Madison
- Hauptermittler: Gabrail Nashat, MD, CEO, President, Gabrail Cancer Center
- Hauptermittler: Martha Glenn, MD, Associate Professor of Medicine, Huntsman Cancer Institute, Salt Lake City
- Hauptermittler: Andre Goy, MD, Director of Lymphoma and Deputy Director of Cancer Center, Hackensack University Medical Center, Hackensack
- Hauptermittler: Roger Lyons, MD, President, Cancer Care Centers of South Texas , San Antonio
- Hauptermittler: Nishitha Reddy, MD, Vanderbilt University Medical Center, Nashville
- Hauptermittler: Reena Nair, MD, Professor and Medical Oncologist, Tata Memorial Hospital, Mumbai, India
- Hauptermittler: Anand Pathak, MD, Medical Oncologist, Cancer Care Clinic and Hospital, Nagpur, India
- Hauptermittler: Vinod Raina, MD, Head Dept of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India
- Hauptermittler: N K Warrier, MD, Senior Consultant Oncologist, Malabar Institute of Medical Sciences, Calicut, India
- Hauptermittler: Cecil Ross, MD, Consultant Oncologist, St. Johns Medical College & Hospital, Bangalore, India
- Hauptermittler: Kirushna kumar, MD, Consultant Oncologist, Meenakshi mission hospital and research centre, Madurai, India
- Hauptermittler: S H Advani, MD, Consultant Oncologist, Jaslok Hospital and Research Centre, Mumbai, India
- Hauptermittler: Patrick Johnston, MD, Associate Professor of Medicine, College of Medicine, Mayo Clinic, Rochester, USA
- Hauptermittler: Ajay Gopal, MD, Associate Professor of Medicine, Department of Medicine, University of Washington, Seattle, Washington.
- Hauptermittler: Craig Reeder, MD, Consultant, Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Arizona
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- P276-00/23/08
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Mantelzell-Lymphom
-
Bing HanAbgeschlossenPure Red Cell Aplasia, erworbenChina
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI); Genentech, Inc.RekrutierungDiffuses großzelliges B-Zell-Lymphom | Wiederkehrendes diffuses großzelliges B-Zell-Lymphom | Refraktäres diffuses großzelliges B-Zell-Lymphom | Primäres mediastinales (thymisches) großes B-Zell-Lymphom | Follikuläres Lymphom Grad 3b | Transformierte follikuläre Lymphe zu Diff Large B-Zell-Lymphom und andere BedingungenVereinigte Staaten
-
Johnson & Johnson Pharmaceutical Research & Development...Abgeschlossen
-
Peking Union Medical College HospitalUnbekannt
-
Johnson & Johnson Pharmaceutical Research & Development...AbgeschlossenReine Erythrozyten-AplasieVereinigtes Königreich, Schweden, Südafrika, Brasilien, Kanada, Deutschland, Norwegen, Thailand
-
National Cancer Institute (NCI)AbgeschlossenAIDS-bedingtes peripheres/systemisches Lymphom | AIDS-assoziiertes diffuses großzelliges Lymphom | AIDS-bedingtes diffuses gemischtzelliges Lymphom | AIDS-bedingtes kleines Noncleaved-Cell-LymphomVereinigte Staaten
-
Beijing Friendship HospitalBeijing Boren HospitalNoch keine RekrutierungLangerhans-Zell-HistiozytoseChina
-
Fundació Institut de Recerca de l'Hospital de la...Rekrutierung
-
GlaxoSmithKlineAbgeschlossenLangerhans-Zell-HistiozytoseVereinigte Staaten
Klinische Studien zur P276-00
-
Piramal Enterprises LimitedAbgeschlossenMelanomAustralien, Indien, Neuseeland
-
Piramal Enterprises LimitedAbgeschlossenRezidiviertes und/oder refraktäres multiples MyelomIndien
-
Piramal Enterprises LimitedBeendet
-
Piramal Enterprises LimitedAbgeschlossenNeubildungKanada, Indien
-
Piramal Enterprises LimitedAbgeschlossenStrahleninduzierte Mukositis bei Kopf- und HalskrebsIndien
-
Instituto Nacional de Enfermedades RespiratoriasAbgeschlossenSchlafen | Entscheidungsfindung | Praktikum und AufenthaltMexiko
-
Piramal Enterprises LimitedAbgeschlossen
-
Piramal Enterprises LimitedBeendet
-
University of TorontoDiabetes Canada; Wharton Medical ClinicNoch keine RekrutierungHyperglykämie | Fettleibigkeit | Diabetes mellitus, Typ 2 | Prädiabetischer ZustandKanada
-
National Institute of Allergy and Infectious Diseases...Centers for Disease Control and Prevention; International AIDS Vaccine Initiative und andere MitarbeiterZurückgezogen